Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 25, No 36 (December 20), 2007: pp. 5731-5737
© 2007 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2007.11.1476

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mauer, M. E.L.
Right arrow Articles by van den Bent, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mauer, M. E.L.
Right arrow Articles by van den Bent, M. J.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Prognostic Value of Health-Related Quality-of-Life Data in Predicting Survival in Patients With Anaplastic Oligodendrogliomas, From a Phase III EORTC Brain Cancer Group Study

Murielle E.L. Mauer, Martin J.B. Taphoorn, Andrew Bottomley, Corneel Coens, Fabio Efficace, Marc Sanson, Alba A. Brandes, Carin C.D. van der Rijt, Hans J.J.A. Bernsen, Marc Frénay, Cees C. Tijssen, Denis Lacombe, Martin J. van den Bent

From the European Organisation for Research and Treatment of Cancer, Quality of Life Unit, Data Center, and the Data Center Brain Group, Brussels, Belgium; Medical Center Haaglanden/Westeinde Hospital, Den Haag; Erasmus University Medical Center, Rotterdam; Canisius Wilhelmina Ziekenhuis, Nijmegen; St Elisabeth Ziekenhuis, Tilburg, the Netherlands; Centre Hospitalier Universitaire Pitié-Salpêtrière, Paris; Centre Antoine Lacassagne, Nice, France; and Azienda Sanitaria Locale Ospedale Bellaria-Maggiore, Bologna, Italy

Address reprint requests to Murielle Mauer, PhD, European Organisation for Research and Treatment of Cancer Data Center, Quality of Life Unit, Ave Mounier 83/11, Brussels, Belgium 1200; e-mail: murielle.mauer{at}eortc.be

Purpose This is one of a few studies that have explored the value of baseline symptoms and health-related quality of life (HRQOL) in predicting survival in patients with brain cancer.

Patients and Methods Baseline HRQOL scores (from the European Organisation for Research and Treatment of Cancer [EORTC] Quality of Life Questionnaire C30 and the EORTC Brain Cancer Module) were examined in 247 patients with anaplastic oligodendrogliomas to determine the relationship with overall survival by using Cox proportional hazards regression models. Refined techniques as the bootstrap resampling procedure and the computation of C indexes and R2 coefficients were used to explore the stability of the models as well as better assess the potential benefit of using HRQOL to predict survival in clinical practice and research.

Results Classical analysis controlled for major clinical prognostic factors selected emotional functioning (P = .0016), communication deficit (P = .0261), future uncertainty (P = .0481), and weakness of legs (P = .0001) as statistically significant prognostic factors of survival. However, several issues question the validity of these findings and no single model was found to be preferable over all others. C indexes, which estimate the probability of a model to correctly predict which patient among a randomly chosen pair of patients will survive longer, and R2 coefficients, which measure the proportion of variability explained by the model, did not exhibit major improvement when adding selected or all HRQOL scores to clinical factors.

Conclusion While classical techniques lead to positive results, more refined analyses suggest that baseline HRQOL scores add relatively little to clinical factors to predict survival. These results may have implications for future use of HRQOL as a prognostic factor for patients with cancer.

Supported in part by Grant Nos. 5U10CA11488-30 through 5U10CA11488-34 from the National Cancer Institute and by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Cancer Group; also supported by the EORTC Charitable Trust.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Neuro OncologyHome page
R. Liu, M. Page, K. Solheim, S. Fox, and S. M. Chang
Quality of life in adults with brain tumors: Current knowledge and future directions
Neuro Oncology, June 1, 2009; 11(3): 330 - 339.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2007 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online